TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9278201
Drug: Chloroquine (2.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (2.1 g base total dose) with Prednisolone
Study: 9278201
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment with Prednisolone
Study: 3105310
Drug: 200 g
Normalized name: PEG-200 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g of carbohydrate in an isocaloric diet
Study: 3105310
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of carbohydrate in an isocaloric diet
Study: 29607766
Drug: FAIS-specific physical
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAIS-specific physical therapy group received personalized progressive strengthening and functional retraining.
Study: 22266043
Drug: Single-agent pemetrexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent pemetrexed
Study: 24486883
Drug: LY545694 (25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY545694 (25mg twice daily)
Study: 24486883
Drug: Gabapentin (600mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (600mg 8 hours apart; 6 doses over 3 days)
Study: 22221173
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ursodeoxycholic acid (UDCA) at 17-23 mg/kg/day
Study: 22221173
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ursodeoxycholic acid (UDCA)
Study: 20556559
Drug: Flavocoxid (569
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavocoxid (569 mg HED)
Study: 20556559
Drug: Flavocoxid combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavocoxid combined with aspirin (370 mg HED)
Study: 2123065
Drug: Mild induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild induction chemotherapy in patients aged greater than or equal to 70 and/or with concurrent nonhematologic disorders (28 patients)
Study: 2123065
Drug: Conventional induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional induction chemotherapy in eligible patients (52 patients)
Study: 2123065
Drug: Supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive care alone in patients not suitable for induction chemotherapy (23 patients)
Study: 30672195
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of Hegu needling and Shu needling techniques at the positive reaction points
Study: 11960953
Drug: Tyramine infusion
Normalized name: tyramine
DrugBank: Tyramine (DB08841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyramine infusion
Study: 17507322
Drug: etravirine 800
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: etravirine 800 mg bid
Study: 17507322
Drug: etravirine 400
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: etravirine 400 mg bid
Study: 16286387
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral corticosteroids (CS) used by 13 RA patients
Study: 16286387
Drug: No corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No corticosteroid treatment (RA patients without CS and healthy controls)
Study: 12401595
Drug: IV fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV fentanyl (10 micro g/kg bolus followed by 10 micro g. kg(‐1). h(‐1) infusion)
Study: 12401595
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl (2 micro g/kg)
Study: 12401595
Drug: IV fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV fentanyl (10 micro g/kg bolus and 10 micro g. kg(‐1). h(‐1))
Study: 2297150
Drug: Metaproterenol (Alupent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaproterenol (Alupent inhalation solution)
Study: 6125394
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily doses of clobazam
Study: 6125394
Drug: Divided daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided daily doses of clobazam
Study: 29576505
Drug: Siponimod 2
Normalized name: siponimod 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siponimod 2 mg once daily
Study: 25029702
Drug: Dairy meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy meal (3 servings providing 1350 mg calcium)
Study: 19580368
Drug: Inhaled cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled cyclosporine (ACsA) 300 mg, 3 days a week for 2 years
Study: 19580368
Drug: Inhaled cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled cyclosporine (ACsA)
Study: 16750618
Drug: Combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy with SM (15 mg/kg intramuscularly three times per week for the initial 3 months)
Study: 16750618
Drug: Combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy without SM
Study: 16750618
Drug: Combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy with SM
Study: 16246987
Drug: Creatinine clearance
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatinine clearance (CrCl) of 30 mL/min or lower (<= 0.50 mL/s)
Study: 16246987
Drug: Creatinine clearance
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatinine clearance (CrCl) higher than 90 mL/min (> 1.50 mL/s)
Study: 16246987
Drug: Participants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with CrCl of 30 mL/min or lower (<= 0.50 mL/s)
Study: 16246987
Drug: Moderate kidney
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate kidney impairment (CrCl between 30 mL/min and 90 mL/min)
Study: 28432376
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg MDMA
Study: 18794647
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg MDMA
Study: 2084208
Drug: Cavit-G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cavit-G
Study: 27034623
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g CrN (CrN-Low)
Study: 27034623
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g CrN (CrN-High)
Study: 27034623
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g CrM
Study: 18830857
Drug: Rosiglitazone 8
Normalized name: rosiglitazone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 8 mg for 24 weeks
Study: 18830857
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg and 8 mg)
Study: 16647684
Drug: 3-day hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-day hormone free interval (HFI)
Study: 16647684
Drug: Continuing active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing active pills
Study: 16647684
Drug: 21/7-day pre-extension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21/7-day pre-extension cycle with heavier daily flow ratings
Study: 16647684
Drug: 21/7-day pre-extension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21/7-day pre-extension cycle with lighter daily flow ratings
Study: 14659770
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 4IU every other day for 3 months
Study: 9491200
Drug: Dpt rush
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dpt rush immunotherapy
Study: 8412148
Drug: Alcohol (0.32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.32 ml/kg)
Study: 25330837
Drug: DHEA 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 75 mg daily for three consecutive menstrual cycles prior to IVF cycles
Study: 25330837
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no DHEA treatment)
Study: 16700374
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with carbamazepine (Group A, n = 16)
Study: 16700374
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with carbamazepine and phenytoin (Group B, n = 16)
Study: 16700374
Drug: No drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drugs (Group C, n = 18)
Study: 12853784
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (AA) 1 gm twice daily
Study: 6087129
Drug: Cholecystokinin-octapeptide (CCK-OP)
Normalized name: Cholecystokinin C-terminal octapeptide
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cholecystokinin-octapeptide (CCK-OP) treatment: 1 mg/ml solution, two drops, three times daily for one month
Study: 6087129
Drug: Soy flour
Normalized name: soy flour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy flour treatment: 30 gm, three times daily for one month
Study: 6087129
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CCK-OP and soy flour treatments
Study: 24861828
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral 17β-estradiol (0.5 mg/d)
Study: 24861828
Drug: Low-dose venlafaxine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose venlafaxine hydrochloride extended release (75 mg/d)
Study: 18536860
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 mcg once daily
Study: 18060091
Drug: Placebo (usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (usual care minus inhaled anticholinergics)
Study: 10335761
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 40 mg twice daily
Study: 12828751
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 60 mg twice daily
Study: 10335761
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 120 mg twice daily
Study: 10335761
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 240 mg twice daily
Study: 10335761
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 60 mg twice daily for 6 months
Study: 10335761
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 80 mg twice daily for 3 months
Study: 10335761
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 240 mg once daily for 12 months
Study: 10335761
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl (various doses)
Study: 7785008
Drug: Expiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expiratory muscle training (EMT) for 15 minutes twice daily for four weeks using a pressure threshold device; expiratory threshold set at 30% of PEmax.
Study: 4081404
Drug: Nalidixic acid
Normalized name: Nalidixic Acid
DrugBank: Nalidixic acid (DB00779)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalidixic acid (1 g X 3)
Study: 4081404
Drug: Pivmecillinam (200‐400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam (200‐400 mg X 3)
Study: 27163502
Drug: FF/LEVO (100/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/LEVO (100/200 μg) as a fixed-dose combination (FDC)
Study: 27163502
Drug: FF (110
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF (110 μg)
Study: 27163502
Drug: LEVO (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEVO (200 μg)
Study: 20547984
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid (ATRA) 20 mg/m²/d plus chemotherapy (cisplatin and paclitaxel)
Study: 20547984
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus chemotherapy (cisplatin and paclitaxel)
Study: 20547984
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid (ATRA) plus chemotherapy (cisplatin and paclitaxel)
Study: 16061839
Drug: Hydroalcoholic 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroalcoholic 2.5% testosterone gel applied to scrotal skin (1 g, n = 54)
Study: 16061839
Drug: Hydroalcoholic 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroalcoholic 2.5% testosterone gel applied to non-scrotal skin (5 g, n = 56)
Study: 16061839
Drug: Androderm patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androderm patches (2 patches/day, n = 52)
Study: 16061839
Drug: Hydroalcoholic 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroalcoholic 2.5% testosterone gel (scrotal and non-scrotal)
Study: 16061839
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (scrotal gel, non-scrotal gel, patch)
Study: 3286040
Drug: Aspirin, 325
Normalized name: Aspirin, 325 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 325 mg daily
Study: 3286040
Drug: Aspirin, 325
Normalized name: Aspirin, 325 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 325 mg three times daily
Study: 3286040
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus dipyridamole (325 mg and 75 mg, respectively, three times daily)
Study: 2680158
Drug: Sulfinpyrazone (267
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfinpyrazone (267 mg three times daily)
Study: 15811142
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three times daily)
Study: 3286040
Drug: Aspirin daily
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin daily
Study: 3286040
Drug: Aspirin three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin three times daily
Study: 3286040
Drug: All aspirin-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: All aspirin-containing regimens
Study: 30778004
Drug: ILSM and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ILSM and metformin (ILSM+Met)
Study: 27734980
Drug: Steroids +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids + Kabat physical rehabilitation
Study: 24518152
Drug: High-dose grape
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose grape seed extract (200 mg/d)
Study: 24518152
Drug: Low-dose grape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose grape seed extract (100 mg/d)
Study: 23329572
Drug: Transplantation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transplantation of autologous mesenchymal stem cells (MSCs) from G-CSF-mobilised peripheral blood
Study: 20826993
Drug: Narrow-band UV-B
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-band UV-B (TL-01) phototherapy, twice-weekly for 3 months
Study: 20826993
Drug: Oral 8-Methoxsalen
Normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 8-Methoxsalen PUVA, twice-weekly for 3 months
Study: 16698007
Drug: Aspirin 200
Normalized name: aspirin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 200 mg/day
Study: 16698007
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 1 g/day
Study: 10781643
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 400 mg/day
Study: 8225684
Drug: Voltaren (V)
Normalized name: Voltarene
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Voltaren (V) 100 mg tablet
Study: 8225684
Drug: Diclogesic (D)
Normalized name: Dologesic
DrugBank: Phenyltoloxamine (DB11160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diclogesic (D) 100 mg tablet
Study: 7622644
Drug: Astemizole 10
Normalized name: astemizole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole 10 mg
Study: 21082306
Drug: Invisalign treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invisalign treatment
Study: 29384762
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (traditional rehabilitative treatment)
Study: 27356528
Drug: High-sodium and
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sodium and bicarbonate mineral water (BW, sodium 1 g/L; bicarbonate 2 g/L)
Study: 23140347
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy (112 patients, 22.5% of total)
Study: 23140347
Drug: Non-ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ICD therapy (385 patients)
Study: 12358251
Drug: Tegaserod 2
Normalized name: tegaserod 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 2 or 6 mg b.i.d. (n = 1679)
Study: 12358251
Drug: Tegaserod iv.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod iv. single doses (0.8 mg to 20 mg)
Study: 1664903
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) subfraction, initial dose of 17 to 95 U/kg and continuous dose of 7 to 20 U/kg/hr
Study: 7247733
Drug: Fenofibrate 300mg
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate 300mg daily for 1 year
Study: 26359512
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg (high-dose statin therapy)
Study: 26359512
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg (low-dose statin therapy)
Study: 17409969
Drug: Gefitinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (250 mg/day)
Study: 14739683
Drug: Agalsidase alfa
Normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Agalsidase alfa enzyme replacement therapy
Study: 8839837
Drug: Low-dose sIL-1RI
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sIL-1RI
Study: 8839837
Drug: High-dose sIL-1RI
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sIL-1RI
Study: 8839837
Drug: sIL-1RI (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: sIL-1RI (both doses)
Study: 6385681
Drug: Diltiazem, 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem, 360 mg/day
Study: 29551030
Drug: Eltrombopag (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (25 mg/d)
Study: 23857041
Drug: Automatic titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automatic titration guided by the BIS (dual-loop group)
Study: 23857041
Drug: Manual target-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual target-controlled infusion of propofol and remifentanil (manual TCI group)
Study: 20956635
Drug: Fixed starting
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed starting dose
Study: 17026488
Drug: RSG/MET fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSG/MET fixed-dose combination therapy (AVANDAMET) 4 mg/1000 mg up-titrated to 8 mg/2000 mg
Study: 17026488
Drug: RSG/MET fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSG/MET fixed-dose combination therapy (AVANDAMET)
Study: 10722500
Drug: Amprenavir, 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amprenavir, 1,200 mg twice daily over 4 days (seven doses)
Study: 10722500
Drug: Clarithromycin, 500
Normalized name: Clarithromycin, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin, 500 mg twice daily over 4 days (seven doses)
Study: 10722500
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amprenavir and clarithromycin over 4 days (seven doses of each drug)
Study: 1444526
Drug: 0.3 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g/kg IVIG at two week intervals
Study: 3932106
Drug: Dexchlorpheniramine maleate
Normalized name: Dexchlorpheniramine Maleate
DrugBank: Dexchlorpheniramine (DB13679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexchlorpheniramine maleate 6 mg b.i.d.
Study: 25139882
Drug: Glucagon 25
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon 25 μg
Study: 25139882
Drug: Glucagon 75
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon 75 μg
Study: 25139882
Drug: Glucagon 125
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon 125 μg
Study: 25139882
Drug: Glucagon 175
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon 175 μg
Study: 25139882
Drug: High insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High insulin levels (0.05 units/kg/h)
Study: 20706110
Drug: Intermittent CPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent CPT (thrice weekly)
Study: 20706110
Drug: Daily CPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily CPT